公开(公告)号：US20230138444A1

公开(公告)日：2023-05-04

申请号：US17802558

申请日：2021-03-01

申请人： AIC246 AG & Co. KG

发明人： Helmut BUSCHMANN ,  Thomas GOLDNER ,  Jessica REDMER ,  Jordi Carles CERON BERTRAN ,  Andrea HAWE ,  Matthias LUCKE ,  Dorothea HOHMANN ,  Monica ROSA

IPC分类号： A61K31/517 ,  A61K47/10 ,  A61K47/26 ,  A61K47/18 ,  A61K47/32 ,  A61K9/19

摘要： The present invention relates to new stable pharmaceutical compositions containing 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid and sodium ions that are essentially free from complexing solubilizing agents, such as PEG, cyclodextrin, lysine, arginine, in particular HPBCD. The invention further relates to methods of preparation of said pharmaceutical compositions. The invention further relates to use of said pharmaceutical compositions in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.

公开(公告)号：US20230135144A1

公开(公告)日：2023-05-04

申请号：US18089652

申请日：2022-12-28

申请人： EMCURE PHARMACEUTICALS LTD.

发明人： Sougata Pramanick ,  Aasiya Aslam Burhan ,  Mukund Keshav Gurjar ,  Hiren Pravinbhai Patel ,  Deepak Pragjibhai Gondaliya

IPC分类号： A61K9/00 ,  A61K31/175 ,  A61K47/26

摘要： The present invention relates to a ready-to-use solution of carmustine that does not require dissolution or dilution of the carmustine prior to addition to saline and dextrose parenteral solutions. In particular, the invention relates to a stable liquid pharmaceutical composition containing carmustine in the form of ready-to-use solution and method for preparing the same.

公开(公告)号：US20230134228A1

公开(公告)日：2023-05-04

申请号：US17915476

申请日：2021-03-30

申请人： Pawan Kumar SINGH ,  Sarita SINGH ,  Vaishali Hanmantrao GAIKWAD ,  Aditi Hanmantrao GAIKWAD

发明人： Pawan Kumar SINGH ,  Sarita SINGH ,  Vaishali Hanmantrao GAIKWAD ,  Aditi Hanmantrao GAIKWAD

IPC分类号： A61K36/58 ,  A61K36/752 ,  A61K36/899 ,  A61K36/53 ,  A61K36/534 ,  A61K36/324 ,  A61K36/61 ,  A61K36/23 ,  A61K36/71 ,  A61K36/81 ,  A61K36/185 ,  A61K36/8945 ,  A61K36/48 ,  A61K36/82 ,  A61K36/9068 ,  A61K36/484 ,  A61K36/54 ,  A61K36/889 ,  A61K47/10 ,  A61K47/26

摘要： Disclosed herein are formulations of a poly-herbal synergistic composition which exhibit marked immunomodulatory, anticancer, antiviral and anti-inflammatory properties. Also disclosed are the methods of preparing and using the same.

公开(公告)号：US20230133762A1

公开(公告)日：2023-05-04

申请号：US18087506

申请日：2022-12-22

申请人： Insmed Incorporated

发明人： Jeff WEERS

IPC分类号： A61K31/496 ,  A61K9/00 ,  A61K9/14 ,  A61K31/7034 ,  A61K9/127 ,  A61K31/7036 ,  A61K31/7048 ,  A61K45/06 ,  A61M11/00 ,  A61M11/02 ,  A61M15/00 ,  A61M15/08 ,  A61K47/26

摘要： A system for treating or providing prophylaxes against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

公开(公告)号：US20230132438A1

公开(公告)日：2023-05-04

申请号：US17309874

申请日：2021-01-05

申请人： CannaXan GmbH

发明人： Werner Brand

IPC分类号： A61K36/185 ,  A61K9/10 ,  A61K47/26 ,  A61P25/04 ,  A61K47/24 ,  A61K47/34

摘要： A formulation contains at least one natural cannabis material, at least one solvent, and at least one stabilizer. The formulation is a liquid suspension having a particle size (D90) of below 500 nm. The formulation can be used in the treatment of a disease.

公开(公告)号：US11639391B2

公开(公告)日：2023-05-02

申请号：US16604031

申请日：2018-04-18

申请人： DR. REDDY'S LABORATORIES LIMITED

发明人： Murali Jayaraman ,  Pravin Nair ,  Navneet Kaur ,  Deepak Thumbrahalli

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K47/26 ,  C07K16/32

摘要： The present invention provides a stable liquid formulation of an antibody in phosphate-amino acid based dual buffer system. The antibody formulated in phosphate-amino acid based dual buffer system imparts optimum stability to the antibody, at lower as well as higher concentrations. Further, the antibody formulated in phosphate-amino acid based buffer system has low viscosity and is suitable for therapeutic administration of high concentrations of antibody.

公开(公告)号：US11639381B2

公开(公告)日：2023-05-02

申请号：US16793208

申请日：2020-02-18

申请人： H. LUNDBECK

发明人： Roger K. Cady ,  Jeffrey T. L. Smith ,  Joseph Hirman ,  Barbara Schaeffler ,  Lahar Mehta

IPC分类号： C07K16/18 ,  A61P25/06 ,  A61K45/06 ,  A61K31/4172 ,  A61K39/00 ,  A61K38/00 ,  A61K9/00 ,  A61K39/395 ,  A61K47/26

摘要： Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.

公开(公告)号：US11638714B2

公开(公告)日：2023-05-02

申请号：US17094297

申请日：2020-11-10

申请人： MOUNTAIN VALLEY MD INC

发明人： Michael Farber

IPC分类号： A61K31/7048 ,  A61K47/69 ,  A61K9/00 ,  A61K47/26 ,  A61K9/127 ,  A61K9/08

摘要： Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 10-20 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

公开(公告)号：US11638692B2

公开(公告)日：2023-05-02

申请号：US17965253

申请日：2022-10-13

申请人： Azurity Pharmaceuticals, Inc.

发明人： Indu Muni ,  Peter Mione ,  Anisa Gandhi ,  Cristina LeChiara

IPC分类号： A61K9/08 ,  A23L2/52 ,  A23L2/56 ,  A23L2/60 ,  A61K38/14 ,  A61K47/12 ,  A61K47/26 ,  A61K9/00

摘要： The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

公开(公告)号：US20230125871A1

公开(公告)日：2023-04-27

申请号：US17912398

申请日：2021-03-17

申请人： GI INNOVATION, INC.

发明人： Myung Ho JANG ,  Young Min OH ,  Heonchang LIM

IPC分类号： A61K9/08 ,  A61K38/20 ,  A61K38/17 ,  A61K47/22 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26

摘要： The present invention relates to a pharmaceutical formulation with enhanced stability of a fusion protein dimer comprising a modified IL-2 protein and a CD80 protein. The fusion protein dimer comprising an IL-2 protein and a CD80 protein can not only activate immune cells owing to IL-2, but also effectively regulate Treg cells owing to CD80. When the formulation according to the present invention is applied to a fusion protein dimer comprising an IL-2 protein and a CD80 protein, the stability of the fusion protein dimer is significantly increased, and it can be used as a liquid formulation. Accordingly, the commercial applicability of the fusion protein dimer can be increased.